Literature DB >> 15708949

Psoriatic arthritis and psoriasis: role of patient advocacy organisations in the twenty first century.

G M Zimmerman1, L M Savage, D C Chandler, M Maccarone Buonfigli.   

Abstract

All the psoriatic arthritis and psoriasis patient advocacy organisations are devoted to promoting public awareness and patient education; supporting access to effective treatments and physicians committed to the welfare of patients; working with physicians and other organisations to facilitate development of new treatments; and supporting research for more effective treatments and a cure for psoriasis and psoriatic arthritis. They have participated in the remaking of health politics in the late twentieth century. This was an era in which small patient support and advocacy groups were transformed into sophisticated national health organisations integral to the formation of national health policy and research, treatment, and education funding by working with physicians, legislators, pharmaceutical companies, third party payors, and the media. As we enter the twenty first century, some of these groups have done critical surveys of patients and physicians to discern needs that are redirecting their programming and reshaping directions in the field. Many national leagues have united to form international organisations. Although differences in their national healthcare systems, the age of their organisations, and the diseases they cover are reflected in the focus of their individual activities, much unites them. Whatever their size, as their roles have come to be recognised in the healthcare community, the patient advocacy organisations welcome being invited to the decision making table. This report describes a sampling of these organisations.

Entities:  

Mesh:

Year:  2005        PMID: 15708949      PMCID: PMC1766887          DOI: 10.1136/ard.2004.033225

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  11 in total

Review 1.  Cost-effectiveness of TNF-alpha-blocking agents in the treatment of rheumatoid arthritis.

Authors:  Sonja Merkesdal; Jörg Ruof; Thomas Mittendorf; Henning Zeidler
Journal:  Expert Opin Pharmacother       Date:  2004-09       Impact factor: 3.889

Review 2.  Recent advances in the treatment of the seronegative spondyloarthropathies.

Authors:  C T Ritchlin; B E Daikh
Journal:  Curr Rheumatol Rep       Date:  2001-10       Impact factor: 4.592

Review 3.  Scientific contributions of ankylosing spondylitis patient advocacy groups.

Authors:  E Feldtkeller; J Bruckel; M A Khan
Journal:  Curr Opin Rheumatol       Date:  2000-07       Impact factor: 5.006

Review 4.  Psoriasis: epidemiology, clinical features, and quality of life.

Authors:  R G B Langley; G G Krueger; C E M Griffiths
Journal:  Ann Rheum Dis       Date:  2005-03       Impact factor: 19.103

5.  Fine mapping of the PSORS4 psoriasis susceptibility region on chromosome 1q21.

Authors:  F Capon; S Semprini; S Chimenti; G Fabrizi; G Zambruno; S Murgia; C Carcassi; M Fazio; R Mingarelli; B Dallapiccola; G Novelli
Journal:  J Invest Dermatol       Date:  2001-05       Impact factor: 8.551

6.  Differences in the expression of spondyloarthropathy: a comparison between ankylosing spondylitis and psoriatic arthritis.

Authors:  D D Gladman; B Brubacher; D Buskila; P Langevitz; V T Farewell
Journal:  Clin Invest Med       Date:  1993-02       Impact factor: 0.825

7.  Psoriatic arthritis and CARD15 gene polymorphisms: no evidence for association in the Italian population.

Authors:  Emiliano Giardina; Giuseppe Novelli; Antonio Costanzo; Steven Nisticò; Cristina Bulli; Cecilia Sinibaldi; Maria Laura Sorgi; Sergio Chimenti; Francesco Pallone; Egisto Taccari; Paola Borgiani
Journal:  J Invest Dermatol       Date:  2004-05       Impact factor: 8.551

8.  Ankylosing spondylitis in the pharaohs of ancient Egypt.

Authors:  Ernst Feldtkeller; Ernst-Martin Lemmel; Anthony S Russell
Journal:  Rheumatol Int       Date:  2002-09-13       Impact factor: 2.631

9.  A modified version of the Health Assessment Questionnaire (HAQ) for psoriatic arthritis.

Authors:  J A Husted; D D Gladman; J A Long; V T Farewell
Journal:  Clin Exp Rheumatol       Date:  1995 Jul-Aug       Impact factor: 4.473

10.  The utility of the arthritis impact measurement scales for patients with psoriatic arthritis.

Authors:  C M Duffy; K N Watanabe Duffy; D D Gladman; B B Brubacher; D Buskila; P Langevitz; V T Farewell
Journal:  J Rheumatol       Date:  1992-11       Impact factor: 4.666

View more
  1 in total

Review 1.  Perspectives on decisions for treatment and care in severe asthma.

Authors:  Tonya Winders; Jorge Maspero; Luke Callan; Mona Al-Ahmad
Journal:  World Allergy Organ J       Date:  2021-01-16       Impact factor: 4.084

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.